Condition: Gastric Adenocarcinoma · Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Sponsor: Toray Industries, Inc
This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarcinoma.
This description comes directly from the study's public registry record.
(Asia sites)Toray Contact for Clinical Trial Information · +81 467-32-9948 · npdd-clinical.toray.mb@mail.toray
(US sites) Contact for Clinical Trial Information · 954-612-8596 · lmullins@td2inc.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| City of Hope at Orange County Lennar Foundation Cancer Center | Irvine, California, United States | Recruiting |
| University of California, Los Angeles | Santa Monica, California, United States | Recruiting |
| Texas Oncology Arlington North | Arlington, Texas, United States | Recruiting |
| Texas Oncology Bedford | Bedford, Texas, United States | Recruiting |
| Texas Oncology Dallas Methodist | Dallas, Texas, United States | Recruiting |
| Texas Oncology Dallas Medical City | Dallas, Texas, United States | Recruiting |
| Texas Oncology Dallas Presbyterian | Dallas, Texas, United States | Recruiting |
| Texas Oncology Methodist Charlton Cancer Center | Dallas, Texas, United States | Recruiting |
| Texas Oncology-Sammons Cancer Center | Dallas, Texas, United States | Recruiting |
| Texas Oncology Fort Worth Cancer Center | Fort Worth, Texas, United States | Recruiting |
| Texas Oncology Grapevine | Grapevine, Texas, United States | Recruiting |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06038578